# Prioritization of risk genes in multi sclerosis by a refined Bayesian framework followed by tissue-specificity and cell type feature assessment
Source codes of three major parts are provided:
  1. Refined iRIGS for MS risk gene prioritization
  2. Two-sample Mendelian randomization (2SMR) analyses
  3. Drug repositioning using Cogena 

# References
Wang Q, Chen R, Cheng F, Wei Q, Ji Y, Yang H, Zhong X, Tao R, Wen Z, Sutcliffe JS et al: A Bayesian framework that integrates multi-omics data and gene networks predicts risk genes from schizophrenia GWAS data. Nat Neurosci 2019, 22(5):691-699.

Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, Langdon R et al: The MR-Base platform supports systematic causal inference across the human phenome. Elife 2018, 7.

Jia Z, Liu Y, Guan N, Bo X, Luo Z, Barnes MR: Cogena, a novel tool for co-expressed gene-set enrichment analysis, applied to drug repositioning and drug mode of action discovery. BMC Genomics 2016, 17:414.
